Background. Blood cultures are approximately 50% sensitive for diagnosing invasive candidiasis. The T2Candida nanodiagnostic panel uses T2 magnetic resonance and a dedicated instrument to detect Candida directly within whole blood samples.
cultures, is not dependent on recovery of viable organisms [10] . The panel detects the 5 most common pathogenic Candida species (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei). In a multicenter trial (DIRECT), per-sample sensitivity and specificity of T2Candida were 91.1% and 99.4%, respectively, as determined by testing whole blood from almost 1500 patients with negative blood cultures, 6 patients with candidemia, and 250 contrived samples seeded with various concentrations of the 5 species [11] . The mean time to Candida detection and species identification was 4.4 ± 1.0 hours. To date, there is limited experience with T2Candida in testing clinical samples from patients with candidemia [10] [11] [12] .
The objective of this prospective, multicenter trial (DIRECT2) was to determine the sensitivity of T2Candida among hospitalized patients with candidemia. Patients with candidemia due to species detected by T2Candida were identified by diagnostic blood cultures (dBCs). After dBCs were reported as positive, follow-up blood samples were collected concurrently for testing by T2Candida and companion cultures. Therefore, 2 groups of patients were enrolled: those in whom diagnostic and companion blood culture (cBCs) were positive for Candida and those in whom diagnostic cultures were positive but subsequent companion cultures were negative. The primary endpoint was clinical sensitivity of T2Candida at the time of positive cBCs. The secondary endpoint was T2Candida performance among patients with recent candidemia, in whom blood cultures were no longer positive. To reflect real-world clinical practice, antifungal therapy was permitted prior to collection of T2Candida samples and cBCs.
METHODS

Patient Enrollment
Patients were enrolled from March 2012 through August 2013 at 14 centers (Supplementary Table S1 ). The institutional review boards of each institution approved the study. Procedures were in accordance with the Helsinki Declaration. Written informed consent was obtained from all patients. Patients aged 18-95 years were enrolled after a dBC collected during their current hospitalization was reported as positive for a Candida species. Data are not available on the body sites from which dBCs were obtained. Patients were excluded if they received a noncommercially available drug within 30 days prior to T2Candida blood sample collection or if the dBC was only positive for Candida species not included in the T2Candida panel.
Sample and Data Collection
Three whole blood T2Candida samples (4 mL) and aerobic and anaerobic blood cultures (cBCs, 5-10 mL) were collected in that order from the same site. T2Candida samples were collected in K 2 EDTA plastic vacutainer tubes (Becton Dickinson, Franklin Lakes, New Jersey) supplied by T2 Biosystems. Uncentrifuged tubes were placed immediately in frozen storage (−70°C to −80°C) and shipped overnight on dry ice to T2 Biosystems. Sample 1 was distributed to the central study lab (Miriam Hospital, Providence, Rhode Island) for testing; if the volume was <4 mL, sample 2 was tested. The third sample from each patient was saved for possible future studies. Blood cultures were processed immediately in accordance with standard institutional practices using an FDA-cleared or clinically accepted test method at each site. Cultures were incubated for 5 days or until a positive result was reported. Species were identified using standard commercial methods from Vitek (bioMérieux, Durham, North Carolina), API (bioMérieux), Remel (San Diego, California), or BD Phoenix (Becton Dickinson). Demographic, clinical, and microbiologic data were collected using a case report form.
T2Candida Testing
Whole blood samples were thawed at room temperature over 12 hours in the central lab prior to T2Candida testing. Fully automated testing was performed in the T2Dx instrument on blinded samples, according to manufacturer's specifications. T2Dx lyses red blood cells, concentrates Candida cells and cellular debris, lyses cells by mechanical bead-beating, amplifies Candida DNA using a thermostable polymerase and primers for the intervening transcribed spacer 2 region within the ribosomal DNA operon, and detects amplified product by amplicon-induced agglomeration of supermagnetic particles and T2MR measurement [11] . An internal control (synthetic DNA target) and positive and negative T2Candida external controls were processed with each run. If the internal control was invalid and there was no positive T2MR signal, the T2Candida result was deemed invalid. The test readout is positive or negative for C. albicans/C. tropicalis, C. glabrata/C. krusei, and C. parapsilosis without quantitative data. In other words, a positive result for C. albicans/C. tropicalis indicates at least 1 of these species was detected. The grouping of species is based on typical antifungal susceptibility patterns [11, 12] .
Statistical Analyses
T2Candida and cBCs were positive if they detected a Candida species that was identified in the corresponding dBC. The clinical sensitivity of T2Candida was defined using positive cBCs as the reference. Continuous variables are presented as median and range, and categorical data are presented as relative frequencies. Factors associated with test results were identified using Fisher exact, Wilcoxon, or McNemar tests. Variables with P ≤ .10 by univariate analysis were included in multivariate logistic regression analysis. Statistical significance was defined as P < .05.
RESULTS
Study Patients and Sample Collection
A total of 184 patients with candidemia were identified; 15 were excluded due to incomplete records and 17 were excluded due to invalid T2Candida results. Therefore, the study analyzed results for 152 patients (Figure 1) . Demographic, clinical, and microbiologic data are presented in Table 1 .
In 96% (146/152) of patients, a single Candida species was recovered from the dBC; in the remaining patients, 2 Candida species were recovered. Candida albicans (30%; n = 46), C. glabrata (30%, n = 45), and C. parapsilosis (28%, n = 43) were most common (Tables 1 and 2 ). The median time to detection of Candida by dBCs was 42.5 hours (range, 13.9-122.6); the median time from detection of Candida to species identification was 81.0 hours (range, 10.5-469.5; Table 2 ).
The median time between collection of dBCs and T2Candida samples/cBCs was 55.5 hours (range, 16.4-148.4). In 74% (112/152) of patients, at least 1 dose of an antifungal agent was administered prior to obtaining the T2Candida sample/cBC (Table 1) . Agents included echinocandins (n = 79, 52%), azoles (n = 51, 34%), and amphotericin B formulations (n = 8, 5%).
The median duration of antifungal treatment prior to sample collection was 12.5 hours (range, 1.2-53.6).
Performance of T2Candida and Companion Blood Cultures
T2Candida and cBCs were positive for an original infecting Candida species, as identified by dBC, in 45% (69/152) and 24% (36/152) of patients, respectively (P < .0001, McNemar; Table 2  and Supplementary Table S2 ). In the absence of prior antifungal therapy, T2Candida and cBCs were positive in 32.5% (13/40) and 30% (12/40) of patients, respectively. The respective tests were positive in 50% (56/112) and 21% (24/112) of patients who were receiving antifungal therapy (P = .0005, McNemar).
In 1% (2/152) of patients, T2Candida was defined as negative because the Candida species detected was different from what was detected in the dBC. In 3% (5/152) of patients, T2Candida detected a species identified by dBC and an additional species Figure 1 . Combined performance of T2Candida and companion blood cultures (cBCs). A total of 184 patients with diagnostic blood cultures positive for Candida were identified initially. Fifteen and 17 patients were excluded due to incomplete records and invalid T2Candida results, respectively. The former group included 1 patient in whom there was a technical error in loading the T2Candida cartridge into the T2Dx instrument. A, The performance of T2Candida and cBCs for the final cohort of 152 enrolled patients. B, Results for patients who were receiving or not receiving antifungal therapy when T2Candida samples/cBCs were collected. Included in the T2+/cBC− group were patients originally infected with Candida albicans (n = 18), Candida parapsilosis (n = 7), Candida tropicalis (n = 6), Candida glabrata (n = 5), and Candida krusei (n = 1). The T2−/cBC+ group included 3 patients who were originally infected with C. glabrata and 1 patient who was originally infected with C. parapsilosis. Among patients who were excluded from the study due to invalid T2Candida results, 88% (15/17) of cBCs were negative for Candida species and 12% (2/17) of cBCs were positive for Candida species (Supplementary Table S3 ). If invalid results are taken as negative, the combined performance of T2Candida and cBCs in Figure 1A is as follows: T2+/cBC+, 19% (32/169); T2+/cBC−, 22% (37/169); T2−/cBC+, 4% (6/169); and T2−/cBC−, 56% (94/169). The clinical sensitivity of T2Candida if invalid results are taken as negative is 84% (32/38). Abbreviations: AF, antifungal; cBC, companion blood culture; dBC, diagnostic blood cultures; T2, T2Candida. that was not identified by diagnostic or cBC (C. glabrata/C. krusei, n = 3; C. albicans/C. tropicalis, n = 1; C. parapsilosis, n = 1). Each positive cBC revealed a species that was present in the corresponding diagnostic culture.
Neutropenia (P = .047), prior antifungal treatment (P = .01), and C. albicans candidemia P = .015) were independently associated with positive T2Candida results (Table 3 ). In the absence of prior antifungal treatment, the only factor associated with T2Candida positivity was shorter time to positive dBC (P = .03). Among patients who received antifungal therapy, neutropenia (P = .01) and C. albicans candidemia (P = .005) were independently associated with T2Candida positivity.
No risk factor was significantly associated with positive cBCs in the entire cohort or among patients who received antifungal therapy. In the absence of antifungal therapy, positive cBCs were significantly more likely with a shorter time to positive dBC (median, 26.6 vs 38.4 hours; P = .03, Wilcoxon).
Combined Performance of T2Candida and Companion Blood Cultures
Combined T2Candida and cBC results are summarized in Figure 1 and Table 4 . The clinical sensitivity of T2Candida was 89%, as positive results were obtained in 32/36 of patients with positive cBCs. In 1 patient, the cBC was positive for 2 Candida species (C. glabrata and C. parapsilosis). T2Candida was positive for C. glabrata/C. krusei and C. parapsilosis.
T2Candida and cBCs were both positive (T2+/cBC+) or both negative (T2−/cBC−) in 21% (32/152) and 52% (79/152) of patients, respectively. T2+/cBC− results were obtained in 24% (37/152) of patients. Factors that were independently associated with T2+/cBC− results were neutropenia (P = .01), prior antifungal treatment (P < .0001), and C. albicans candidemia (P < .0001), similar to the findings for T2Candida positivity in general (Table 5 ). T2−/cBC+ results were obtained in 3% (4/152) of patients. In 2 of these patients, the T2Candida sample was clotted when the assay was performed.
DISCUSSION
In this study, we validated the clinical sensitivity of the T2Candida panel for the diagnosis of bloodstream infections caused by the 5 most common pathogenic Candida species. T2Candida was 89% sensitive in patients with positive cBCs, a result that was remarkably similar to the analytic sensitivity of 91.1% for contrived blood samples in the DIRECT trial [11] . The panel also performed comparably to cBCs among patients with recent candidemia who were not receiving antifungal agents (32.5% and 30% positive, respectively). The performance of both tests in these patients was consistent with the natural history of untreated candidemia, in which blood cultures often clear spontaneously within 48 hours [13] [14] [15] . Positive T2Candida and cBCs in the absence of antifungal exposure were associated with shorter times to dBC positivity, suggesting that higher initial Candida burdens contributed to the results. The data demonstrate that T2Candida reliably diagnosed candidemia when collected at a time that blood cultures were positive. T2Candida may improve the management of candidemia by shortening times to Candida detection and species identification compared to blood cultures, thereby facilitating more rapid institution of definitive antifungal therapy [11] . Echinocandins administered as monotherapy were micafungin (n = 34), caspofungin (n = 13), and anidulafungin (n = 10). Azoles administered as monotherapy were fluconazole (n = 26), voriconazole (n = 3), and posaconazole (n = 1). T2Candida was significantly more likely to be positive than cBCs among the entire patient cohort (45% vs 24%; P < .0001). T2+/cBC− results were obtained in 24% of patients, whereas T2−/ cBC+ results were obtained in only 3% of patients. Antifungal treatment was independently associated with T2Candida positivity and with T2+/cBC− results. T2Candida and blood cultures are capable of detecting Candida at concentrations <1 colony-forming unit per milliliter [11, 12, 16] . In a given patient, particularly one infected with a low burden of Candida close to the limit of detection, it is plausible that T2Candida or blood culture may be positive while the other test is negative. At the same time, T2Candida provides a potential advantage over blood cultures by detecting nonviable, growth-inhibited or latent Candida, which may be particularly relevant during antifungal treatment [5, 10] . In keeping with our T2+/cBC− data, several case reports of candidemia have described persistent T2Candida positivity among antifungal-treated patients despite rapid sterilization of blood cultures [10] . An important clinical implication of these findings is that T2Candida is likely to diagnose at least some cases of candidemia that would be missed by cultures during preemptive or empiric antifungal treatment. The current study was not designed to assess the performance of T2Candida in monitoring responses to definitive antifungal therapy. In patients who received antifungal agents, T2+/BC− results may be a marker for inadequate responses, reflecting the presence of nonproliferating or latent cells that can seed target organs and/or serve as a reservoir for relapsing infection [5, 17, 18] . Alternatively, the results may be indicative of effective treatment, signifying the presence of nonviable Candida cells.
Complementary data from this study and DIRECT now provide an excellent sense of how T2Candida is likely to perform in clinical practice. In DIRECT, the per-patient specificity of T2Candida was 98.1% and the per-test specificity of T2Candida was 99.4% [11] . Based on the clinical sensitivity of T2Candida demonstrated here, positive and negative predictive values (PPVs, NPVs) at various pretest likelihoods of candidemia can be calculated (Table 6 ). The PPV of T2Candida among hospitalized patients in whom blood cultures are collected for any indication is anticipated to be only about 15%. However, PPVs increase rapidly if T2Candida is used in patients in whom candidemia is more likely. In contrast to PPVs, anticipated T2Candida NPVs are excellent in all groups at risk for candidemia. Based on these values, T2Candida is not expected to have significant clinical value if used routinely at very low pretest likelihoods of candidemia because PPVs are likely insufficient to justify antifungal treatment and a negative result does not appreciably lessen the probability of candidemia. However, in patients at greater risk for candidemia, such as critical care unit residents with unexplained fevers, those in septic shock, or those who fulfill criteria of various clinical prediction scores, PPVs may exceed a threshold that justifies antifungal treatment, while corresponding NPVs render active candidemia extremely unlikely. The strong NPVs of T2Candida may be useful for antifungal stewardship and in decisions to withhold or discontinue treatment. Rational T2Candida testing and patient management decisions must be taken on a case-by-case basis, considering clinical details, microbiology and laboratory data, and other factors particular to the patient. Furthermore, the utility of T2Candida will depend on local epidemiology. Species currently included in the T2Candida panel account for more than 95% of invasive candidiasis [12] , but the microbiology of candidemia and antifungal susceptibility patterns can differ by center [35, 36] .
In addition to antifungal treatment, neutropenia and C. albicans candidemia were independently associated with positive T2Candida and T2+/cBC− results. It is well recognized that neutropenic patients are at increased risk of developing blood culture-negative, deep tissue complications of candidemia, even if they receive antifungal prophylaxis [37] . In studies of febrile neutropenia, Candida polymerase chain reaction assays on blood samples were more sensitive than cultures in patients with probable or autopsy-proven candidiasis [38, 39] . Our finding that T2Candida performed well during neutropenia is T2Candida positive for given species, and companion blood culture positive for given species. a Number of isolates is 155 because 6 patients had 2 Candida species identified in diagnostic blood cultures (C. albicans + C. dubliniensis, n = 3; C. albicans + C. glabrata, n = 1; C. glabrata + C. parapsilosis, n = 1; C. glabrata + C. krusei, n = 1). Candida dubliniensis isolates (n = 3) are not included in the T2Candida results did not differ by center, site of blood draw, culture method, or antifungal regimen (data not included in Table) . noteworthy because prompt diagnosis of candidemia and early antifungal therapy may be particularly beneficial in immunosuppressed hosts [40] . The biologic explanation for the association between C. albicans candidemia and T2Candida positivity is unknown. In general, C. albicans concentrations during candidemia fall between the higher burdens of C. parapsilosis, which is usually associated with intravenous catheters, and the lower burdens of C. glabrata, which usually causes disease after gastrointestinal tract translocation [5, 16] . Within this window, it is plausible that the sensitivity of T2Candida over blood cultures is optimized. Of note, T2Candida was positive in more patients infected with each of the non-C. albicans species than blood cultures; however, differences did not reach statistical significance.
There are several limitations to this study. Its design is not consistent with how T2Candida will be used most commonly in clinical practice, which will be among patients at some risk for candidemia but without prior positive blood cultures. The study design does not allow us to definitively conclude that T2Candida is more sensitive than blood cultures because the biologic significance of T2+/cBC− results is unclear. A lack of detailed information on treatment regimens and patients' outcomes also limited our ability to draw conclusions about the clinical significance of combined Abbreviations: +, positive test, as defined by detection of a Candida species identified by diagnostic blood culture; %, percentage of total N for a given column; cBC, companion blood culture; T2, T2Candida.
T2Candida-cBC results. Since T2Candida testing was performed in batches at a central laboratory, we could not measure the turnaround time for reporting of results. T2Candida samples were frozen and thawed prior to testing, which may have contributed to invalid results or otherwise impacted performance. Indeed, invalid results were obtained in 9% of patients initially identified for this study, which was consistent with a 7.6% rate for thawed samples in DIRECT [11] . Invalid results may stem from the presence of inhibitors in whole blood samples [10] . Testing of recollected samples from patients with invalid results is recommended; however, T2Candida performance in this setting requires further study [11] . Data are needed on rates of invalid results in routine clinical practice using freshly collected samples and on the impact of such results on costs. Along these lines, the present study did not assess T2Candida cost-effectiveness. Modeling studies have suggested that T2Candida may achieve overall cost savings by reducing unnecessary antifungal usage [12] , but these findings require prospective validation. Finally, T2Candida performance described here is specific for candidemia. Limited data for deep-seated candidiasis have shown that the panel can identify at least some blood culture-negative cases [11, 12] .
In conclusion, T2Candida is an important advance in the diagnosis of candidemia. The panel is the first commercial application of T2MR technology in a diagnostic assay and it ushers in a new era in which rapid molecular testing for invasive candidiasis will serve as an adjunct to microbiologic cultures. Issues that warrant investigation in future studies include T2Candida performance during blood culture-negative, deep-seated candidiasis; significance of T2+/BC− results in different clinical settings; roles of T2Candida in monitoring antifungal responses and predicting patients' outcomes; cost-effectiveness in various settings; and validation that management strategies that incorporate T2Candida shorten time to appropriate antifungal use, reduce inappropriate antifungal use, improve outcomes, and limit the emergence of resistance. In the DIRECT trial, there were 5 true-positive T2Candida results and 28 presumed false-positive T2Candida results. Therefore, the 15% positive predictive value calculated here based on the assumption of 90% sensitivity/98% specificity was identical to that measured in DIRECT (15%, 5/33). Table 3 . Factors not listed in Table 5 
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